LQDA Stock Analysis: Liquidia Technologies | NASDAQ

Inhaled Powder, Injectable Infusion, Liposomal Formulation, Particle Engineering

Total Rating 60

Safety 33

Buy Signal -0.04

Drug Manufacturers - Specialty & Generic
Industry Rotation: -0.3

Market Cap: 6.15B
Avg Turnover: 87.6M

Risk 3d forecast

Volatility72.9%

VaR 5^th Pctl11.6%

VaR vs Median-3.17%

Reward TTM

Sharpe Ratio1.64

Rel. Str. IBD95.7

Rel. Str. Peer Group86.3

Character TTM

Beta0.727

Beta Downside-0.636

Hurst Exponent0.577

Drawdowns 3y

Max DD46.80%

CAGR/Max DD2.55

CAGR/Mean DD7.72

EPS (Earnings per Share)

Last SUE: -4.00
Qual. Beats: -1

Revenue

Rev. CAGR: 227.68%
Rev. Trend: 82.3%

Last SUE: -2.61
Qual. Beats: -1

Warnings

Strong Share Dilution

Beneish M-Score Likely Earnings Manipulation

Below Avwap Earnings

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 8 years of data

Jan +9.9% 30

Feb +5.7% 32

Mar +0.7% 20

Apr -5.8% 28

May +11.6% 24

Jun -6.3% 46

Jul -2.5% 27

Aug -6.3% 6

Sep -2.7% 10

Oct +2.2% 24

Nov +5.9% 29

Dec +11.3% 30

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: LQDA Liquidia Technologies

Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company founded in 2004 and headquartered in Morrisville, North Carolina. The company focuses on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases, with a particular emphasis on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead product candidate, YUTREPIA, is an inhaled dry-powder formulation of treprostinil targeting both PAH and PH-ILD. The company also distributes Remodulin, a continuously infused treprostinil injection, and is advancing L606, an inhaled liposomal treprostinil formulation currently in Phase III clinical trials for the same indications.

In addition to its therapeutics business, Liquidia operates a proprietary particle engineering platform called PRINT, which enables precise control over the size, geometry, and chemical composition of drug particles. This technology underpins the companys inhaled delivery approach and is also licensed to third parties, including partnerships with GlaxoSmithKline, Alcon, Vectura, the University of North Carolina at Chapel Hill, and Pharmosa Biopharm. The company has a promotion agreement with Sandoz supporting the commercialization of its treprostinil-based portfolio.

Liquidia trades as a mid-cap stock in the Health Care sector (GICS Sub-Industry: Pharmaceuticals) and went public in July 2018. Its business model combines specialty drug development for rare diseases-where treprostinil, a prostacyclin analog, is a standard-of-care therapy-with a technology licensing component, giving it multiple potential revenue streams across both product sales and platform partnerships.

Headlines to Watch Out For

YUTREPIA FDA approval and commercial launch for PAH
United Therapeutics patent dispute ruling impacts generic Tyvaso entry
L606 phase III results for inhaled treprostinil formulation

Piotroski VR-10 (Strict) 7.0

Net Income: 138.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 59.76 > 1.0
NWC/Revenue: 55.09% < 20% (prev 606.4%; Δ -551.3% < -1%)
CFO/TA 0.15 > 3% & CFO 79.0m > Net Income 138.6m
Net Debt (-148.4m) to EBITDA (177.8m): -0.83 < 3
Current Ratio: 2.31 > 1.5 & < 3
Outstanding Shares: last quarter (101.4m) vs 12m ago 18.47% < -2%
Gross Margin: 92.48% > 18% (prev 70.36%; Δ 22.12% > 0.5%)
Asset Turnover: 115.7% > 50% (prev 7.51%; Δ 108.2% > 0%)
Interest Coverage Ratio: 6.61 > 6 (EBIT TTM 176.1m / Interest Expense TTM 26.6m)

Altman Z'' 3.67

A: 0.48 (Total Current Assets 437.7m - Total Current Liabilities 189.3m) / Total Assets 521.9m
B: -0.96 (Retained Earnings -498.7m / Total Assets 521.9m)
C: 0.45 (EBIT TTM 176.1m / Avg Total Assets 389.7m)
D: 0.60 (Book Value of Equity 195.1m / Total Liabilities 326.8m)
Altman-Z'' = 3.67 = AA

Beneish M 1.00

DSRI: 0.47 (Receivables 108.6m/9.97m, Revenue 450.9m/19.3m)
GMI: 0.76 (GM 70.36% / 92.48%)
AQI: 0.47 (AQ_t 0.09 / AQ_t-1 0.19)
SGI: 23.34 (Revenue 450.9m / 19.3m)
TATA: 0.11 (NI 138.6m - CFO 79.0m) / TA 521.9m)
Beneish M = 12.03 (Cap -4..+1) = D

What is the price of LQDA shares?

As of September 12, 2026, the stock is trading at USD 66.74 with a total of 778,472 shares traded. Over the past week, the price has changed by -2.75%, over one month by -24.20%, over three months by -6.83% and over the past year by +147.19%.

Current recommended Stop Loss: 57.70 (which is 13.5% or 2.6 ATR below the current price).

Is LQDA a buy, sell or hold?

Liquidia Technologies has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy LQDA.

StrongBuy: 6
Buy: 3
Hold: 0
Sell: 0
StrongSell: 1

What are the forecasts/targets for the LQDA price?

Analysts Target Price	107.8	61.4%

Liquidia Technologies (LQDA) - Fundamental Data Overview as of 07 September 2026

Market Cap USD = 6.15b (6.15b USD * 1.0 USD.USD)
P/E Trailing = 49.0429
P/E Forward = 10.6952
P/S = 13.6296
P/B = 31.4566
Revenue TTM = 450.9m USD
EBIT TTM = 176.1m USD
EBITDA TTM = 177.8m USD
Long Term Debt = 122.2m USD (from longTermDebt, last quarter)
Short Term Debt = 899k USD (from shortTermDebt, last quarter)
Debt = 135.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.79m
Net Debt = -148.4m USD (calculated: Debt 135.7m - CCE 284.2m)
Enterprise Value = 6.00b USD (6.15b + Debt 135.7m - CCE 284.2m)
Interest Coverage Ratio = 6.61 (Ebit TTM 176.1m / Interest Expense TTM 26.6m)
EV/FCF = 99.11x (Enterprise Value 6.00b / FCF TTM 60.5m)
FCF Yield = 1.01% (FCF TTM 60.5m / Enterprise Value 6.00b)
FCF Margin = 13.42% (FCF TTM 60.5m / Revenue TTM 450.9m)
Net Margin = 30.74% (Net Income TTM 138.6m / Revenue TTM 450.9m)
Gross Margin = 92.48% ((Revenue TTM 450.9m - Cost of Revenue TTM 33.9m) / Revenue TTM)
Gross Margin QoQ = 93.27% (prev 90.86%)
Tobins Q-Ratio = 11.49 (Enterprise Value 6.00b / Total Assets 521.9m)
Interest Expense / Debt = 19.62% (Interest Expense 26.6m / Debt 135.7m)
Taxrate = 8.54% (6.97m / 81.7m)
NOPAT = 161.1m (EBIT 176.1m * (1 - 8.54%))
Current Ratio = 2.31 (Total Current Assets 437.7m / Total Current Liabilities 189.3m)
Debt / Equity = 0.70 (Debt 135.7m / totalStockholderEquity, last quarter 195.1m)
Debt / EBITDA = -0.83 (Net Debt -148.4m / EBITDA 177.8m)
Debt / FCF = -2.45 (Net Debt -148.4m / FCF TTM 60.5m)
Total Stockholder Equity = 92.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 35.57% (Net Income 138.6m / Total Assets 521.9m)
RoE = 149.6% (Net Income TTM 138.6m / Total Stockholder Equity 92.6m)
RoCE = 82.01% (EBIT 176.1m / Capital Employed (Equity 92.6m + L.T.Debt 122.2m))
RoIC = 51.80% (NOPAT 161.1m / Invested Capital 311.0m)
WACC = 8.74% (E(6.15b)/V(6.28b) * Re(8.54%) + D(135.7m)/V(6.28b) * Rd(19.62%) * (1-Tc(0.09)))
Discount Rate = 8.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.16 | Cagr: 14.08%
[DCF] Terminal Value 74.07% ; FCFF base≈60.5m ; Y1≈60.8m ; Y5≈64.4m
[DCF] Fair Price = 12.14 (EV 938.3m - Net Debt -148.4m = Equity 1.09b / Shares 89.5m; r=8.74% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 82.27 | Revenue CAGR: 227.7% | SUE: -2.61 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.96 | Chg30d=-0.83% | Revisions=-40% | Analysts=5
EPS current Year (2026-12-31): EPS=3.22 | Chg30d=-7.47% | Revisions=+0% | GrowthEPS=+502.5% | GrowthRev=+366.7%
EPS next Year (2027-12-31): EPS=5.65 | Chg30d=+1.40% | Revisions=+25% | GrowthEPS=+75.5% | GrowthRev=+65.9%
[Analyst] Revisions Ratio: -17% (up=1, down=2)